References
- Musher DM, Rodriguez-Barradas MB. Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant. Hum Vaccin Immunother 2015; 12(2): 331-5; PMID:26606172; http://dx.doi.org/10-1080/21645515.2015.1098794
- Schuchat A. Pneumococcal prevention gets older and wiser. JAMA Intern Med 2015; 175:1897-8; PMID:26502379; http://dx.doi.org/10.1001/jamainternmed.2015.6133
- Hochman M, Cohen PA. Reconsidering guidelines on the use of pneumococcal vaccines in adults 65 years or older. JAMA Intern Med 2015; 175:1895-6; PMID:26502317; http://dx.doi.org/10.1001/jamainternmed.2015.5689
- Moore MR, Whitney CG. Use of pneumococcal disease epidemiology to set policy and prevent disease during 20 years of the emerging infections program. Emerging Inf Dis 2015; 21:1551-56; PMID:26291238; http://dx.doi.org/10.3201/eid2109.150395
- Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the Era of conjugate vaccines. JID 2010; 201:32-41; PMID:19947881; http://dx.doi.org/10.1086/648593
- Andrews A, Waight PA, George RC et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012; 30:6802-8; PMID:23000122; http://dx.doi.org/10.1016/j.vaccine.2012.09.019
- Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114-25; PMID:25785969; http://dx.doi.org/10.1056/NEJMoa1408544